Pharmaceuticals & Therapeutics

With 17 abstracts at AAD 2026, LEO Pharma showcases real-world data to tackle treatment gaps in diverse populations and chronic skin diseases.

IntraBio's landmark FDA submission for levacetylleucine offers the first glimmer of an approved therapy for the devastating rare disease Ataxia-Telangiectasia.

A 30-year-old breakthrough could revolutionize physics and cancer detection. Its inventor now demands a public test to prove it, alleging a cover-up.

A new oral Alzheimer's drug shows potential for a lower, more patient-friendly dose, aiming to replace complex infusions with a simple daily pill.

The pharma giant is acquiring a promising 'best-in-class' PI3Kα inhibitor, SNV4818, in a move to bolster its oncology pipeline and redefine cancer care.

A new book by a top physician-scientist challenges the idea that innovation comes from the private sector, arguing Medicaid is a lab for bold experiments.

ImmunoBrain's novel immunotherapy for Alzheimer's avoids key safety issues of other drugs and shows positive biomarker data in a Phase 1b trial.

LGM Pharma is investing $15 million to expand its Texas and Colorado sites, boosting domestic production of specialized drugs and fortifying the U.S. supply chain.

New data suggests Phanes Therapeutics' bispecific antibody may overcome major side effects of CD47 inhibitors while showing promise in tough GI cancers.

A new partnership will leverage genetically engineered mice to create novel antibody drugs, potentially unlocking treatments for cancer and brain diseases.

The animal health firm posts a 7.9% organic sales jump in 2025, overcoming production hurdles with key acquisitions and a major R&D push.

With late-breaking hypertension data and an AI-driven platform, Kardigan is set to showcase a new, personalized approach to cardiovascular medicine.

Activist investor Altai Capital launches a proxy fight at OraSure, alleging chronic underperformance and demanding board seats to force a strategic review.

The Devil is in the details. A new partnership between Grey Goose and "The Devil Wears Prada 2" redefines brand engagement through film, fashion, and cocktails.

Aldeyra Therapeutics' dry eye drug, reproxalap, was rejected by the FDA for a third time, citing inconsistent data and wiping out millions in value.

A new injectable dye entering Phase 3 trials promises to make lung cancer cells glow, helping surgeons remove tumors more completely and prevent recurrence.

Consumers overcharged for generic drugs may get cash from a new $17.8M settlement. Find out if you're eligible and how this fits into a larger legal war.

A new collaboration will use Voro's 'masking' technology to create tumor-activated ADCs, aiming to make powerful cancer therapies safer and more effective.

Backed by dialysis giants DaVita and U.S. Renal Care, a new startup licenses a first-in-class therapy to transform treatment for kidney patients.

A new biotech firm unveils a first-in-class cancer drug targeting E6AP, aiming to restore the body's natural defenses against HPV-positive head and neck cancer.